

# RAMP 203: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC)

## Study Overview:

The purpose of the first part of the RAMP 203 study (or trial) is to determine the best dose of an investigational drug called avutometinib (VS-676) in combination with an approved drug called sotorasib (LUMAKRAS®) when given to patient with KRAS G12C inhibitor or have experienced disease progression while undergoing therapy with a KRAS G12C inhibitor. The second phase of the RAMP 203 study focuses on the impact of the combination of avutometinib and sotorasib. The trial will measure effectiveness, including overall response rate, as well as safety. The study is being conducted by lung cancer specialists.

Patients who are eligible and agree to participate in this study will be treated with a combination of avutometinib (VS-6766) and sotorasib (LUMAKRAS®), along with follow up appointments to monitor the disease. This is an open-label trial. Every patient will be treated with active oral study drugs that are not being compared to a placebo.

Avutometinib is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA).

## Protocol Title:

RAMP 203: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC)

Protocol Numbers: VS-6766-203 (Verastem, Inc.)

Clinical Trial NCT05074810

Study Drugs or Compounds: Avutometinib (VS-6766) and Sotorasib (LUMAKRAS®)

Study Phase: Phase 1/2

Total Enrollment: Estimated at 121 patients

Study Short Title: RAMP 203: Study of Avutometinib (VS-6766) + Sotorasib in KRAS G12C NSCLC Patients (NSCLC)

Sponsor: Verastem Oncology

For more information see: <https://clinicaltrials.gov/ct2/show/NCT05074810>

